Skip to content

Released May 8, 2025, before the open

10-Q filed May 8, 2025, 38 days after period end · 0001628280-25-023486

Q1 2025 · 10-Q
Revenue$1.45M+146.0% vs Q1 2024−33.4% vs Q4 2024
Net Income-$51.89MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.40N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$52,392,000N/M
Operating Cash Flow-$48,857,000N/M
Free Cash Flowderived-$51,279,000N/M
Margins · derived
Operating margin-3603.3%+4576.2 pt vs Q1 2024
Net margin-3568.8%+4174.2 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$1.45M$591.00K$0.00—
Net Income-$51.89M-$45.76M-$39.40M-$23.84M
EPS Diluted-$0.40-$0.44-$0.44-$1.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR